Symptom response to antibiotic prescribing strategies in acute sore throat in adults: results from the DESCARTE prospective cohort study by Moore, Michael et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/103683/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Moore, Michael, Stuart, Beth, Hobbs, Richard, Butler, Christopher C., Hay, Alastair, Campbell,
John, Delany, Brendan, Broomfield, Sue, Barratt, Paula, Hood, Kerenza, Everitt, Hazel, Mullee,
Mark, Williamson, Ian, Mant, David and Little, Paul 2017. Symptom response to antibiotic
prescribing strategies in acute sore throat in adults: results from the DESCARTE prospective cohort
study. Brtitish Journal of General Practice 67 (662) , e634-e642. 10.3399/bjgp17X692321 file 
Publishers page: http://dx.doi.org/10.3399/bjgp17X692321
<http://dx.doi.org/10.3399/bjgp17X692321>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 1 
 
Symptom response  to antibiotic prescribing strategies in acute sore throat in adults: results from the DESCARTE 
prospective cohort study  
 
 
 
Michael Moore1, Beth Stuart1, F D Richard Hobbs2, Chris C Butler2, Alastair D Hay4,  John Campbell5, 
Brendan C Delaney6 Sue Broomfield1, Paula Barratt1, Kerenza Hood3, Hazel A Everitt1, Mark Mullee1, Ian 
Williamson1, David Mant2 Paul Little1, on behalf of the *DESCARTE investigators 
 
 
Affiliations: 
1. Michael Moore Paul Little, Mark Mullee, Beth Stuart,  Ian Williamson, Paula Barratt, Sue Broomfield, Hazel 
Everitt, Primary Care and Population Sciences Division, University of Southampton, UK 
2. Department of Primary Care Health Sciences,  University of Oxford Radcliffe Primary Care Building,, 
Woodstock Road, Oxford, OX2 6GG  
3. South East Wales Trials Unit, Institute of Primary Care & Public Health, School of Medicine, Cardiff 
University, Cardiff, UK CF14 4YS 
4. Centre for Academic Primary Care, School of Social and Community Medicine, University of Bristol. 
5. University of Exeter Medical School. Exeter, EX1 2LU 
6. Department of Surgery and Cancer, Imperial College, St Mary’s Hospital, London W2 1NY 
 
Tel +44 2380 241050; fax +44 2380 701125 
University of Southampton 
Aldermoor Health Centre, Aldermoor close, Southampton UK 
SO16 5ST 
*DESCARTE stands for Decision rule for the Symptoms and Complications of Acute Red Throat in Everyday practice 
 
 
 
  
 2 
 
 
Abstract 
Background 
A delayed or just in case prescription has been identified as having potential to reduce antibiotic use in sore throat.   
Aim 
To determine the symptomatic outcome of acute sore throat in adults according to antibiotic prescription strategy in routine 
care. 
Design and Setting  A prospective cohort study comprising adults age over 16 presenting with acute sore throat (<=2 
weeks duration) managed with treatment as usual in primary care.  
Methods. A random sample of 2876 from the full cohort were requested to complete a symptom diary. A brief clinical 
proforma was used to collect symptom severity and examination findings at presentation. Outcomes details collected by 
notes review and a detailed symptom diary. The primary outcome was poorer ‘global’ symptom control (defined as longer 
than the median duration or higher than median symptom severity). Analyses controlled for confounding by indication 
(propensity to prescribe antibiotics). 
Results. 1629/2876 (57%) of those requested returned a symptom diary of whom 1512 had information on prescribing 
strategy. The proportion with poorer global symptom control was greater in those not prescribed antibiotics 393/578 
(68%) compared to those prescribed immediate antibiotics 423/723 (60%) or delayed antibiotic prescription 112/193 
(58%); adjusted risk ratio (95% confidence interval), immediate 0.87 (0.70-0.96) p=0.006, delayed 0.88 (0.78-1.00). 
p=0.042.  
Conclusions. In the routine care of adults with sore throats a delayed antibiotic strategy confers similar symptomatic 
benefits to immediate antibiotics compared to no antibiotics. If a decision is made to prescribe an antibiotic, a delayed 
antibiotic strategy is likely to yield similar symptomatic benefit to immediate antibiotics. 
 
Funding: The Medical Research Council. 
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Introduction. 
Acute sore throat is common in everyday primary care practice and antibiotics still frequently prescribed1.  The 
Cochrane review of acute sore throat management included 27 trials and over 12000 cases of sore throat2 and found 
that antibiotics reduced the duration of pain symptoms by an average of one day.  Current UK guidelines recommend a 
delayed or no prescription strategy for acute sore throat. 3 Despite the guidelines and systematic review evidence 
described, most patients presenting with acute sore throat are prescribed immediate antibiotics.1,4. An alternative 
strategy - using a delayed antibiotic prescription - has been shown to reduce antibiotic uptake without any effect on 
recovery or patient satisfaction5 and to confer a similar protective effect against complications compared to an 
immediate prescription6.  However the rationale of a delayed prescription has been called into question since it results 
in higher antibiotic uptake than a no prescription strategy with a suggestion that a delayed strategy was inferior to 
immediate antibiotics for some sore throat symptoms.7 Observational studies provide useful evidence to complement 
experimental studies, given the concerns that randomised trial participants and their behavior during trials (e.g. for 
adherence) may be atypical, and hence that estimates of effectiveness may not be applicable to routinely consulting 
patients. In order to describe current practice and outcome related to prescribing strategy in adults we interrogated a 
large observational cohort which had been recruited to investigate potential prediction of septic complications of acute 
sore throat. In a subset of participants completing a symptom diary, we investigated the symptomatic outcomes and 
illness duration in relation to prescribing strategy. 
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Methods.  
 
Overall study design. 
As reported elsewhere6,8, the study used a simple one page paper/web based clinical proforma documenting clinical 
features to facilitate the generation of a large prospective cohort of patients presenting to general practitioners in the 
UK with acute sore throat and treated as usual.  Smaller studies were nested in the cohort to develop and trial a clinical 
scoring method for bacterial infection. The nested studies were two consecutive diagnostic cohorts (n=1107) where a 
clinical score to predict bacterial infection was developed, and a randomised trial (n=1781) which compared the use of the 
clinical score and the targeted use of a rapid antigen detection test with delayed antibiotic prescribing. 9  Participants in the 
trial were not included in this analysis because antibiotics were targeted according to trial criteria. Initial recruitment was 
among six local Networks (based in Southampton, Bristol, Birmingham Oxford, Cardiff, Exeter) but was extended 
nationally during the last 18 months of recruitment. 
 
Patient inclusion criteria. Previously well subjects aged 16 years and over with acute illness (14 days or less), presenting 
in primary care with sore throat as the main symptom, and with an abnormal examination of the pharynx (identical criteria 
to our previous studies5).  Exclusion criteria were severe mental health problems (e.g. cognitive impairment associated 
with being unable to consent or assess history) and known immune suppression. Practitioners recorded detailed history and 
examination findings as detailed below and then treated as usual. Antibiotic treatment was therefore determined by 
individual practitioners in accordance with their usual practice. 
 
Baseline clinical proforma. This consisted of a simple clinical sheet documenting age, gender, current smoking 
status, prior duration of illness and the presence and severity of baseline symptoms (sore throat, difficulty swallowing, 
fever during the illness, runny nose, cough, feeling unwell, diarrhoea, vomiting, abdominal pain, headache, muscles 
ache, sleep disturbance, earache). Symptoms were recorded using 4 point Likert scales (none, a slight problem, a 
moderately bad problem, a severe problem), and the presence of signs (pus, cervical nodes, temperature, fetor, palatal 
oedema, difficulty speaking due to sore throat). No laboratory tests were specified. 
 
Documentation of primary outcome. 
A request to complete a symptom diary was randomly allocated to a proportion of those recruited to the study to 
achieve a pre-specified target of 1800 diaries. Initial allocation was randomly allocated to 1:10 participants by 
including the diary in recruitment packs. The allocation ratio was altered partway through the study to 1:2 packs in 
most centres on account of observed low return rates. Allocation was to 1:4 recruitment packs in Southampton due to 
the inclusion of an alternative questionnaire. The diary was similar to that used in other studies.5,10 Patients completed 
the diary each night until symptoms resolved, or for up to 14 nights.  Each symptom was scored (0=no problem to 
6=as bad as it could be): sore throat, difficulty swallowing, feeling unwell, fevers, sleep disturbance. Adverse 
symptomatic outcome was defined as being either above the median for symptom severity at days 2-4 or above the 
median duration of moderately bad symptoms, (ie either or both qualified for adverse symptomatic outcome). 
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Other outcomes. 
In order to allow comparison with other studies we also assessed symptom severity on day 2-4 and the duration of 
moderately bad symptoms (in days).5,10 
 
Sample size. Sample size calculations calculated using NQuery sample size program (Statistical Solutions) for the 
main study were based on the prediction of complications- a rare outcome. For the proposed analysis of diary data a 
sample of 1800 patients allowing for 20% loss to follow-up of diaries (900 of whom would not be expected to have 
antibiotics), would have power to detect variables with prevalence between 20% to 80% with an odds ratio of 2 for 
adverse symptomatic outcome among the no antibiotic group.  
 
Analysis. . Duration of symptoms was analysed using Cox regression, linear regression was used for symptom 
severity and generalised linear model with a log-link and binomial distribution for worsening of illness and adverse 
symptomatic outcome. Missing data on outcome was not imputed. We have reported both the univariate statistics as 
well as the relationships after controlling for the severity of all baseline symptoms and clustering of patients by 
practice.  The Centor score is used widely to target treatment at those at higher risk of streptococcal infection, the 
score was derived in an emergency room setting where a score of 3 or more predicted a 32% risk of positive culture11.  
The FeverPAIN score (which comprises fever in the past 24 hours, purulence, rapid (within three days) attendance, 
inflamed tonsils and no cough or cold symptoms), may also be used to predict the probability of streptococcal 
infection in community samples and has been shown to be highly predictive of time to symptom resolution and 
symptom severity.12  We tested for an interaction between Centor/FeverPAIN and antibiotic prescribing strategy- to 
determine if those more likely to have streptococcal infection had evidence of a differential response to antibiotics. We 
used the scores to dichotomise the sample into those more or less likely to have a streptococcal infection, for Centor 
we used the cut point of 3 or more and for FeverPAIN we used the cut point of 0-2 vs. 3 and over. At the cut point of 
0-2 the probability of a streptococcus swab positive result is 26% whilst for those with a score of 3 and above it is 
60%.12  
Analyses were carried out in Stata version 12.1.  To control for potential confounding by indication, we calculated a 
propensity score based on predictors of antibiotic prescribing (none versus immediate and none versus delayed) using 
a chained equations multiple imputation model.  Results are presented both for complete cases and for models with 
significant predictors of the propensity score imputed. Outcome measures were not imputed as it was not possible to 
distinguish between individuals who were missing data because they did not complete a diary when asked and those 
who were not asked to complete one.   
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Results. 
Descriptive data 
In the full cohort study 14610 adult patients were recruited between 10th November 2006 and the 1st June 2009 from 
616 general medical practices. 1629/2876 (57%) returned a symptom diary of whom 1512 had information on 
prescribing strategy. The baseline characteristics of patients recruited and of those who maintained a symptom diary 
are shown in Appendix Table 1. Those given immediate antibiotics had more severe symptoms at baseline and were 
more likely to have a history of fever and severe inflammation or pus on tonsils6. Those returning the diary were 
slightly older, more likely to be female and a non-smoker compared to the whole sample (Appendix Table 1). 
In those returning a diary no antibiotics were prescribed for 587/1512 (39%), immediate antibiotics were for 728/1512 
(48%) and delayed antibiotics for 197/1512 (13%) similar proportions to the full cohort 40%, 42% and 18% 
respectively. In those completing a diary, 60% of those issued a delayed prescription reported using the prescription. 
Delayed prescribing was only reported by those recruited from approximately one half of participating practices 
(52.1%). 
 
Impact of prescribing strategies on symptom control 
When controlling for propensity to prescribe antibiotics, compared with no antibiotics, those prescribed immediate or 
delayed antibiotics experienced a reduction in poorer symptomatic outcomes: no antibiotics 398/587 (68%), immediate 
antibiotics 441/728 (61%), delayed antibiotics 116/197 (58%); Adjusted risk ratio (95% confidence interval), 
immediate 0.87 (0.70-0.96) p=0.006, delayed 0.88 (0.78-1.00) p=0.042 (Table 1). This finding was consistent when 
controlling for baseline severity. Secondary outcomes showed a reduction in symptom severity on days 2-4 (Table 2) 
and on average 1 day less of moderately bad symptoms in those prescribed an immediate antibiotic (No antibiotic: 
median 4 days Inter Quartile Range (IQR) 2 to 7 days; Immediate: median 3 days IQR 2 to 5 days; Delayed: median 3 
days IQR 2 to 6 days.) Hazard ratio (HR) immediate 1.21 (1.07 to 1.38) p=0.004, hazard ratio delayed HR 1.10 (0.92 
to 1.33) p=0.30 (Table 3. The duration of moderately bad symptoms is illustrated in Figure 1 
 
Evidence for a differential effect of antibiotic prescribing among those more likely to have bacterial infection  
Although throat swabs were not collected we can use diary scores to predict the probability of streptococcal infection, 
we created a subgroup defined by a higher Centor Score (3 or above) and FeverPAIN score (3 or above)12. In the 
subgroup where bacterial infection was more likely, the estimates of benefit are slightly greater for those given an 
immediate antibiotic prescription or delayed prescription than in the whole cohort.   (Table 4 and Table 5).  However, 
the difference with the main cohort were modest and we were not powered for, and did not find, statistically significant 
interactions with these subgroups. The fact that those in the high risk subgroups were overwhelmingly treated with 
immediate antibiotics further reduced the power of these analyses, particularly for the smaller numbers given delayed 
prescription. Individual secondary outcomes are detailed in (Appendix table 2&3). Point estimates for those at 
low/high risk of streptococcal infection are given in Appendix table 4 and 5. 
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Table 1 
 
Table 2 
 
Table 3 
 
Figure 1 Proportion experiencing symptoms rated moderately bad or worse according to receipt of antibiotic 
prescription. 
 
Table 4 
 
Table 5 
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Discussion. 
 
Summary 
 
This large cohort of patients presenting to general practice with acute sore throat enabled us to study the effect of 
prescribing antibiotics in routine practice on symptom severity and speed of illness resolution. Compared to a no antibiotic 
strategy a delayed antibiotic strategy confers similar benefits to immediate antibiotics with regards to effects on global 
symptom outcome. Those prescribed immediate antibiotics experienced both a reduction in symptom severity on day 2-4 
and a reduction in the duration of moderately bad symptoms of one day. Similar benefits were observed in those receiving 
a delayed prescription although this study has limited power for some outcomes in this group. Symptomatic benefits 
arising from delayed or ‘just in case’ prescribing are seen in routine care and are similar to those observed in clinical trials 
of this strategy13. 
 
Strengths and limitations. 
The study was designed using a simple clinical proforma to minimise selection bias and thus to produce a large 
generaliseable prospective cohort. Patients were recruited at the busiest seasons for respiratory illness, and, as with other 
studies of acute infection,14-16 documentation of the details of those not approached was poor due to time pressures (since 
time pressure to recruit also meant time pressure to document non recruitment).  The large sample gathered in routine 
practice along with the inclusion of diary data enabled the study of different antibiotic strategies and duration of 
prescription on symptomatic outcomes and re-consultation, which is likely to reflect the real life experience of patients. 
The prescription of antibiotics however is not at random and there is clear evidence of a greater propensity to prescribe for 
those with more severe symptoms at baseline (Appendix Table 1).  We have adjusted for propensity to prescribe and also 
present outcomes controlled for baseline severity of symptoms but cannot rule out residual confounding.  It is possible that 
those given a prescription for antibiotics subsequently altered their reporting of symptom severity having had their illness 
‘validated’ by the doctor or the converse in those not in receipt of a prescription.  Any study using self reported diary data 
may be open to such misclassification bias but if we accept at face value the reported symptoms then the symptoms 
recorded in the diary will reflect the patient experience of illness. In this observational data set we do not know how 
delayed prescribing was operationalised, but regardless of this, a delayed prescription conferred similar symptomatic 
benefits to an immediate prescription with lower prescription uptake.  
 
Comparison with existing literature 
In routine care in England 42% of those presenting with an acute sore throat illness receive an immediate antibiotic 
prescription and 18% a delayed prescription and antibiotics for acute sore throat are generally well targeted to those with 
most severe symptoms and those most likely to benefit17.  In this sample, 60% of those issued a delayed prescription 
reported using the prescription, which is greater than that reported in experimental studies5.  Overall use of antibiotics is 
similar in the US (60%)18, whereas in France and the Netherlands, reported prescribing rates are lower (20% & 23% 
respectively) although this is aggregated data for all respiratory consultations.19  As would be anticipated, there is some 
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symptomatic benefit in those receiving an antibiotic comparable to that seen in systematic reviews and this effect is also 
seen in those in receipt of a delayed prescription.2,5 
Although the study was not powered to find an interaction of the effect of antibiotic prescribing strategy with the 
likelihood of streptococcal infection, the point estimates for poorer symptomatic outcome with a no prescription strategy 
are more pronounced, which suggests that increased likelihood of streptococcal infection may make symptomatic benefit a 
little more likely when antibiotics are prescribed. Once again there was no clear benefit from immediate antibiotics 
compared with delayed antibiotics in this subgroup of individuals. 
 
 
Implications for practice.  
 
Previous systematic reviews have consistently demonstrated that antibiotics confer a modest benefit for symptom relief2 
and this study has confirmed this effect using evidence from routine practice.  We have previously demonstrated that 
antibiotic prescriptions in routine general practice do appear to be targeted at those at greatest risk of streptococcal carriage 
according to baseline characteristics6. Judicious use of antibiotics is an international priority20 and there is potential to 
reduce the uptake of antibiotics through greater use of the delayed prescription technique or through non-prescription.  
Although adoption of the ‘non prescribing strategy’ results in the lowest uptake of antibiotics7, use of a delayed 
prescription may be a useful option where current prescribing rates are high or there is greater concern for complications.  
It is recognised that there is a trade off between lower antibiotic prescribing and patient satisfaction with both doctors and 
practices21 although clinical trials have not demonstrated large differences in satisfaction between immediate and delayed 
prescribing5.  There is also likely a trade off between a global reduction in prescribing and an increased risk of septic 
complications although the absolute increase is very small.22 Delayed prescribing in this study was targeted at those with 
intermediate symptom severity however trials of delayed prescribing in sore throat were not stratified by symptom severity 
and symptomatic outcomes were similar for all groups13, hence it is unlikely that more widespread use of the delayed 
strategy would result in worse symptomatic outcomes. Caution must be exercised in those with greater probability of 
streptococcal infection and although we were unable to demonstrate adverse outcomes in those with higher symptom 
scores using a delayed prescription this may be due to lack of power. In one study using a delayed strategy in combination 
with a symptoms score to target antibiotics did result in both reduced antibiotic consumption and improved outcomes 
compared to empirical delayed prescribing and this may be the optimal strategy10. In routine practice as in trials delayed 
prescribing offers comparable symptom control to immediate prescribing (this study), and we have previously shown it 
reduces re-consultation6 and the risk of septic complications.6 In the full cohort 18% of sore throat consultations concluded 
with the issue of a delayed antibiotic prescription however there is potential for higher rates to be achieved, for instance 
only half of participating practices in this study reported using the delayed strategy.  GPs have been shown to overestimate 
the patient demand for antibiotics23 and the use of a delayed strategy would be one way of countering this overestimation.  
If the majority of those with intermediate symptom severity were offered a delayed prescription total uptake of antibiotics 
would be reduced with no anticipated adverse effects for symptom control, complications or re-consultation.  
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Table 1 Poorer global symptomatic outcome (either greater than median symptom severity in days 2-4 or greater than 
median duration of symptoms) related to antibiotic strategy and antibiotic type 
 
* In the 1512 returning a symptom diary in which the prescribing strategy was detailed 
 
Table 2 Symptom severity on day 2-4 according to antibiotic prescription strategy  
 Mean symptom 
severity (s.d.) 
 
Difference 
95% CI) p-value 
Difference 
controlling for 
clustering and, 
antibiotic type 
and baseline 
severity score 
(95% CI) p-
value 
Difference 
controlling for 
propensity score 
(95% CI) p-
value 
Difference 
controlling for 
propensity score 
in the imputed 
dataset 
(95% CI) p-
value 
Antibiotic 
prescribing 
strategy 
     
None (reference) 
N=585 
2.13 (1.24)      
Immediate 
N=723 
2.03 (1.20) -0.10  
(-0.23, 0.03) 
p=0.140 
  
-0.30  
(-0.49, -0.21) 
p=0.001  
-0.22  
(0.44, -0.01) 
p=0.040 
-0.22  
(-0.43, -0.01) 
p=0.043  
Delayed 
N=196 
1.95 (1.19)  -0.17 
 (-0.37, 0.02) 
p=0.834 
-0.22  
(-0.42, -0.02) 
p=0.034  
-0.26  
(-0.45, -0.7)  
p=0.009  
-0.26  
(-0.45, -0.07) 
p=0.008  
 Poorer global 
symptomatic 
outcome * 
Univariate risk 
ratio (95% CI) p-
value 
Risk ratio 
controlling for 
baseline severity 
and clustering 
(95% CI) p-
value 
Risk ratio 
controlling for 
propensity score 
(95% CI) p-
value 
Risk ratio 
controlling for 
propensity score 
in imputed 
dataset 
(95% CI) p-
value 
Antibiotic prescribing 
strategy 
     
None 398/587 
(67.80%) 
1.00 1.00 1.00 1.00 
Immediate  441/728 
(60.58%) 
0.88 
(0.81, 0.95) 
p=0.002 
  
0.81  
(0.74, 0.88) 
p<0.001  
0.87 
(0.70, 0.96) 
p=0.006  
0.89  
(0.80, 0.98) 
p=0.024  
Delayed 116/197 
(58.88%) 
0.85  
(0.75, .097) 
p=0.019  
 
0.83  
(0.73, 0.95) 
p=0.007  
0.88  
(0.78, 1.00) 
p=0.042  
0.86  
(0.74, 0.97) 
p=0.016 
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Table 3 Duration of moderately bad symptoms according to antibiotic prescription strategy   
 Duration of 
moderately bad 
symptoms: 
median days 
(IQR) 
Univariate 
hazard ratio 
Hazard ratio 
controlling for 
clustering and 
baseline severity 
score  
(95% CI) p-
value 
Hazard ratio 
controlling for 
propensity score 
(95% CI) p-
value 
Hazard ratio 
controlling for 
propensity score 
in imputed 
dataset 
(95% CI) p-
value 
Antibiotic 
prescribing 
strategy 
     
No 
Antibiotic 
(reference) 
N=587 
4 (2,7) 1.00 1.00 1.00 1.00 
Immediate  
N=728 
3 (2,5) 1.33  
(1.18, 1.50) 
p<0.001  
1.37  
(1.23, 1.53) 
p<0.001  
1.21  
(1.07, 1.38) 
p=0.004  
1.20  
(1.07, 1.3); 
p=0.002  
Delayed 
N=197 
3 (2,6) 1.15  
(0.96, 1.37) 
p=0.120  
1.16  
(0.98, 1.37) 
p=0.084  
1.10  
(0.92, 1.33) 
p=0.300  
1.10  
(0.91, 1.33) 
p=0.316  
 
 
 
Table 4. Effect of probable streptococcal infection – results for participants with a Feverpain score of 3 or more* 
according to antibiotic strategy 
 
 Poorer global 
symptomatic 
outcome 
Interaction 
term (95% CI) 
p-value 
Univariate risk 
ratio (95% CI) 
p-value 
Risk ratio 
controlling for 
baseline 
severity and 
clustering 
(95% CI) p-
value* 
Risk ratio 
controlling for 
propensity 
score 
(95% CI) p-
value 
Risk ratio 
controlling for 
propensity 
score in 
imputed 
dataset 
(95% CI) p-
value 
       
None 
(reference) 
14/20 (70%)  1.00 1.00 1.00 1.00 
Immediate  152/281 
(54.09%) 
0.94  
(0.84, 1.05) 
p=0.253  
 
0.78  
(0.57, 1.05) 
p=0.099 
0.66  
(0.52, 0.84) 
p=0.001  
0.67  
(0.52, 0.87) 
p=0.002  
0.78  
(0.58, 1.04) 
p=0.087  
Delayed  18/32 
(56.25%) 
0.97  
(0.84, 1.13) 
p=0.711  
0.80  
(0.53, 1.22) 
p=0.306  
 
0.79 
 (0.56, 1.13) 
p=0.198  
0.68  
(0.45, 1.04) 
p=0.493 
0.73  
(0.49, 1.07); 
p=0.108 
* FeverPAIN score 1 point for each of fever in the past 24 hours, purulence, rapid (within three days) attendance, 
inflamed tonsils and no cough or cold symptoms 
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Table 5. Effect of probable streptococcal infection – results for participants with a Centor score* of 3 or more 
according to antibiotic strategy 
 
 Poorer global 
symptomatic 
outcome 
Interaction 
term (95% 
CI) p-value 
Univariate risk 
ratio (95% CI) 
p-value 
Risk ratio 
controlling for 
baseline 
severity and 
clustering (95% 
CI) p-value* 
Risk ratio 
controlling for 
propensity 
score 
(95% CI) p-
value 
Risk ratio 
controlling for 
propensity 
score in 
imputed dataset 
(95% CI) p-
value 
       
None 
(reference) 
23/33 
(69.7%) 
 1.00 1.00 1.00 1.00 
Immediate 207/374 
(55.4%) 
0.88  
(0.68, 1.14) 
p=0.345 
  
0.79  
(0.62, 1.01) 
p=0.063  
0.79  
(0.62, 1.00) 
p=0.051  
0.79  
(0.63, 1.00) 
p=0.046  
0.82  
(0.65, 1.03) 
p=0.097 
Delayed  21/43 
(48.8%) 
0.83  
(0.55, 1.23) 
p=0.349 
  
0.70  
(0.48, 1.02) 
p=0.066  
0.72  
(0.49, 1.06) 
p=0.096  
0.64  
(0.45, 0.92) 
p=0.015 
0.65  
(0.45, 0.94) 
p=0.021 
*Centor Score one point for each of tonsillar exudates, swollen tender anterior cervical nodes, lack of a cough, and 
history of fever 
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How this fits in:  Antimicrobial resistance is a major threat to public health   In the UK 75% of antibiotics are prescribed in primary care, mainly for respiratory tract infections  Experimental studies suggests modest symptom benefit when antibiotics are prescribed for sore throat  In routine practice, antibiotics do confer modest symptomatic improvement on average and similar effects are 
seen with delayed and immediate prescribing but delayed prescribing results in reduced antibiotic uptake 
compared to immediate prescribing 
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Appendix 
 
 
Appendix Table 1 Baseline characteristics of the sample including those who returned the symptom diary 
 
 Total cohort  
n=14610 
Patients who completed diaries and where 
prescribing strategy known 
n=1512 
 Not given 
antibiotics 
Given 
antibiotics 
Delayed 
antibiotics 
Not given 
antibiotics 
Given 
antibiotics 
Delayed 
antibiotics 
Clinical assessment       
Number in cohort 6057 6089 2464 587 728 197 
Mean severity of sore 
throat/difficulty 
swallowing on a 4 
point Likert scale 
(SD) 
2.93 (0.72) 3.32 (0.63) 3.06 (0.70) 2.93 (0.68)  3.35  (0.63)  3.01 (0.68)  
Mean severity of all 
baseline symptoms* 
on a 4 point Likert 
scale (SD) 
1.89 (0.39)  2.19 (0.39)  1.99 (0.40)  1.88 (0.40)  2.21 (0.38)  1.95 (0.36)  
Mean FeverPain 
score 
0.33 (0.58)  1.21 (1.09)  0.72 (0.84)  0.26 (0.52)  1.19 (1.11)  0.73 (0.84)  
Prior duration in days 
(SD) 
4.96 (6.48) 4.61 (4.10)  4.29 (3.34)  4.75 (4.14)  4.57 (3.39)  4.17 (3.15)  
Age in years (SD) 34.72 (15.44) 32.65 (14.18) 34.07 (14.57) 37.61  (15.47) 36.04   
(13.85) 
35.68 (14.15) 
Female gender 3,610/5,243 
(68.85%) 
4,147/6,269 
(66.15%) 
1,770/2,501 
(70.77%) 
443/587 
(75.47%)       
521/728 
(71.57%) 
147/197  
(74.62%) 
Smoker 1,016/5,212 
(19.49%) 
1,445/6,240 
(23.16%) 
481/2,484 
(19.36%) 
89/594 
(15.24%) 
 127/726 
(17.49%) 
22/194 
(11.34%) 
Fever in last 24 hours 2,279/4,852 
(46.97%) 
4,109/5,704 
(72.04%) 
1,268/2,317 
(54.73%) 
261/585 
(44.62%) 
515/724 
(71.13%) 
113/197 
(57.36%)  
Temperature oC (SD) 36.66 (0.61)  37.00 (0.75)  36.77 (0.62) 36.64 (0.61) 36.99 (0.74)  36.74 (0.50)  
Pus on tonsils 376/5,213  
(7.21%) 
3,751/6,232 
(60.19%) 
654/2,495 
(26.21%) 
30/581 
(5.16%) 
418/721 
(57.98%) 
50/197 
(25.38%) 
Severely inflamed 
tonsils 
86/4,923  
(1.75%) 
1,418/5,855 
(24.22%) 
178/2,344 
(7.59%) 
6/572 (1.05%) 181/720 
(25.14%) 
12/191 
(6.28%) 
Number of prior 
medical problems 
 
0.22 (0.49) 0.24 (0.51) 0.17 (0.43) 0.28 (0.55)  0.24 (0.51)  0.17 (0.39)  
Return within 4 
weeks with new or 
worsening symptoms 
803/4,974  
(16.14%)  
 
864/5,932 
(14.57%) 
222/2,382 
(9.49%) 
107/564 
(18.97%) 
101/694 
(14.55%) 
24/186 
(12.90%) 
Return within 4 
weeks with 
complications  
 
75/4,974  
(1.51%) 
78/5,932 
(1.31%) 
21/2,382 
 (0.88%) 
12/564 
(2.13%) 
8/694  
(1.15%) 
3/186  
(1.15%) 
Individual 
complications: 
      
           Quinsy 
 
11/4,974 
 (0.22%) 
30/5,932 
(0.52%) 
6/2,382 
 (0.26%) 
4/564  
(0.71%) 
3/694  
(0.43%) 
1/186  
(0.54%) 
           Sinusitis 23/4,974 
(0.46%) 
12/5,932 
(0.21%) 
3/2,382  
(0.13%) 
2/564  
(0.35%) 
0/694 0/186 
           Otitis media 
 
 
31/4,974 
(0.62%) 
27/5,932 
(0.47%) 
11/2,382  
(0.47%) 
5/564  
(0.89%) 
5/694  
(0.72%) 
2/186  
(1.08%) 
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Celluliltis/impetigo 
10/4,974   
(0.20%) 
9/5,932 
 (0.16%) 
1/2,382 
 (0.04%) 
1/564 (0.18%) 0/694 0/186 
*Baseline severity comprised of: sore throat, difficulty swallowing, feeling generally unwell, headache, disturbed sleep, 
muscle ache, fever during illness, fever in the last 24 hours, abdominal pain, diarrhoea, cough during illness, vomiting, 
runny nose, earache, inflamed pharynx, inflamed tonsils, cervical glands 
 
 
 
Appendix Table 2 
Effect of probability of streptococcal infection (FeverPAIN 3 or above) on duration of symptoms, symptom severity 
according to antibiotic prescribing strategy 
 
  
Interaction term Univariate risk 
ratio (95% CI; 
p-value) 
Risk ratio 
controlling for 
baseline 
severity and 
clustering (95% 
CI, p-value)* 
Risk ratio 
controlling for 
propensity 
score 
Risk ratio 
controlling for 
propensity 
score in 
imputed dataset 
 Duration of 
symptoms 
(median, 
IQR) 
     
None 4 (2,7)      
Immediate 3 (2,4) 1.02 (0.87, 
1.19; p=0.819)  
1.26 (0.80, 
1.99; p=0.323)  
1.28 (0.97, 
1.69; p=0.078)  
1.18 (0.88, 
1.57; p=0.278)  
1.16 (0.86, 
1.56; p=0.321) 
Delayed 3 (2,6) 0.92 (0.76, 
1.13; p=0.446)  
0.92 (0.52, 
1.63; p=0.771)  
0.91 (0.60, 
1.37; p=0.643)  
1.04 (0.67, 
1.62; p=0.859)  
1.02 (0.66, 
1.56; p=0.927) 
 Mean 
symptom 
severity score 
 Difference Difference 
controlling for 
clustering and, 
Antibiotic type 
and baseline 
severity score 
(CI) 
Difference 
controlling for 
propensity 
score 
Difference 
controlling for 
propensity 
score in the 
imputed dataset 
None 2.42 (1.32)       
Immediate 1.95 (1.22)  -0.14 (-0.33, 
0.05; p=0.142)  
-0.47 (-1.04, 
0.09; p=0.102) 
-0.68 (-1.19, -
0.17; p=0.010) 
-0.81 (-1.48, -
0.13; p=0.020)  
-0.78 (-1.30, 
0.25; p=0.004)  
Delayed 2.16 (1.35)  -0.02 (-0.26, 
0.22; p=0.884)  
-0.26 (-0.96, 
0.44; p=0.461)  
-0.26 (-0.94, 
0.41; p=0.443)  
-0.41 (-1.07, 
0.26; p=0.222)  
-0.40 (-1.04, 
0.24; p=0.240)  
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Appendix Table 3 
Effect of probability of streptococcal infection (Centor 3 or above) on duration of symptoms, symptom severity according 
to antibiotic prescribing strategy 
 
  
Interaction term Univariate risk 
ratio (95% CI; 
p-value) 
Risk ratio 
controlling for 
baseline 
severity and 
clustering (95% 
CI, p-value)* 
Risk ratio 
controlling for 
propensity 
score 
Risk ratio 
controlling for 
propensity 
score in 
imputed dataset 
 Duration of 
symptoms 
(median, 
IQR) 
     
None 4 (2,6)  1.00 1.00 1.00 1.00 
Immediate 3 (2,4) 1.11 (0.84, 
1.45; p=0.465) 
1.33 (0.90, 
1.95; p=0.153)    
1.32 (1.04, 
1.67; p=0.022)  
1.26 (0.94, 
1.68; p=0.117)  
1.24 (0.94, 
1.64; p=0.134) 
Delayed 3 (2,6) 0.92 (0.59, 
1.44; p=0.733)  
1.10 (0.68, 
1.80; p=0.695)  
1.12 (0.76, 
1.65; p=0.566) 
1.01 (0.64, 
1.61; p=0.953) 
1.05 (0.68, 
1.61; p=0.833)  
 Mean 
symptom 
severity score 
 Difference Difference 
controlling for 
clustering and, 
Antibiotic type 
and baseline 
severity score 
(CI) 
Difference 
controlling for 
propensity 
score 
Difference 
controlling for 
propensity 
score in the 
imputed dataset 
None 2.48 (1.29)       
Immediate 2.00 (1.25)  -0.42 (-0.93, 
0.08; p=0.100)  
-0.48 (-0.93, -
0.03; p=0.035)  
-0.57 (-1.02, -
0.11; p=0.015) 
-0.50 (-0.98, -
0.02; p=0.041)  
-0.49 (-0.98, -
0.01; p=0.044) 
Delayed 2.03 (1.30)  -0.25 (-0.95, 
0.45; p=0.476)  
-0.45 (-1.02, 
0.12; p=0.122)  
-0.37 (-1.00, 
0.26; p=0.249) 
-0.45 (-1.02, -
0.13; p=0.125) 
-0.45 (-1.01, 
0.11; p=0.113) 
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Appendix Table 4 Point estimates for those more and less likely to have streptococcal infection 
(FeverPAIN) 
 
 Poorer symptomatic 
outcome:  
Risk ratio controlling for 
baseline severity and 
clustering (95% CI) 
Duration of symptoms 
Hazard ratio controlling for 
baseline severity and clustering 
(95% CI) 
Mean symptom severity 
score 
Difference controlling for 
clustering and, Antibiotic type 
and baseline severity score (CI) 
 Feverpain
<3 
Feverpain
>=3 
Feverpain<3 Feverpain>=
3 
Feverpain<3 Feverpain>=
3 
None 
(reference) 
1.00 1.00 1.00 1.00   
Immediate  0.87 
(0.79, 
0.96; 
p=0.006) 
0.71 (0.56, 
0.89; 
p=0.004)  
1.27 (1.13, 
1.44; p<0.001) 
1.28 (0.97, 
1.69; 
p=0.078)  
-0.22 (-0.42, 
-0.01; 
p=0.042) 
-0.68 (-1.19, 
-0.17; 
p=0.010)  
Delayed  0.84 
(0.73, 
0.97; 
p=0.014) 
0.81 (0.57, 
1.16; 
p=0.261)  
1.18 (0.99, 
1.42; p=0.072) 
0.91 (0.60, 
1.37; 
p=0.643) 
-0.25 (-0.45, 
-0.05; 
p=0.014) 
-0.26 (-0.94, 
0.41; 
p=0.443)  
 
Appendix Table 5 Point estimates for those more and less likely to have streptococcal infection (CENTOR) 
 
 Poorer symptomatic outcome:  
Risk ratio controlling for 
baseline severity and clustering 
(95% CI) 
Duration of symptoms 
Hazard ratio controlling for 
baseline severity and clustering 
(95% CI) 
Mean symptom 
severity score 
Difference controlling 
for clustering and, 
Antibiotic type and 
baseline severity score 
(CI) 
 Centor<3 Centor>=3 Centor <3 Centor >=3 Centor <3 Centor 
>=3 
None 
(reference) 
1.00 1.00 1.00 1.00   
Immediate  0.87 (0.78, 
0.97; 
p=0.010)  
0.79 (0.62, 
1.00; 
p=0.051)  
1.26 (1.12, 
1.44; 
p<0.001)  
1.32 (1.04, 
1.67; 
p=0.022)  
-0.23 (-
0.45, -
0.02; 
p=0.036)  
-0.57 (-
1.02, -
0.11; 
p=0.015) 
Delayed  0.88 (0.77, 
1.00; 
p=0.046)  
0.72 (0.49, 
1.06; 
p=0.096)  
1.18 (0.98, 
1.43; 
p=0.080)  
1.12 (0.76, 
1.65; 
p=0.566) 
-0.24 (-
0.44, -
0.04; 
p=0.017)  
-0.37 (-
1.00, 0.26; 
p=0.249) 
 
 
 
